Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
10 Jan 2024
10 Jan 2024
Historique:
received:
09
06
2023
accepted:
12
12
2023
medline:
11
1
2024
pubmed:
11
1
2024
entrez:
10
1
2024
Statut:
epublish
Résumé
Malaria, caused by Plasmodium parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts to lower morbidity and mortality. Both advanced candidate vaccines, RTS,S and R21, are subunit (SU) vaccines that target a single Plasmodium falciparum (Pf) pre-erythrocytic (PE) sporozoite (spz) surface protein known as circumsporozoite (CS). These vaccines induce humoral immunity but fail to elicit CD8 + T-cell responses sufficient for long-term protection. In contrast, whole-organism (WO) vaccines, such as Radiation Attenuated Sporozoites (RAS), achieved sterile protection but require a series of intravenous doses administered in multiple clinic visits. Moreover, these WO vaccines must be produced in mosquitos, a burdensome process that severely limits their availability. To reduce reliance on WO while maintaining protection via both antibodies and Trm responses, we have developed an accelerated vaccination regimen that combines two distinct agents in a prime-and-trap strategy. The priming dose is a single dose of self-replicating RNA encoding the full-length P. yoelii CS protein, delivered via an advanced cationic nanocarrier (LION
Identifiants
pubmed: 38200025
doi: 10.1038/s41541-023-00799-4
pii: 10.1038/s41541-023-00799-4
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 1R01AI141857
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 1R01AI141857
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 1R01AI141857
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 1R01AI141857
Informations de copyright
© 2024. The Author(s).
Références
WHO | World malaria report 2018. WHO http://www.who.int/malaria/publications/world-malaria-report-2018/report/en/ (2020).
Mordmüller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445–449 (2017).
pubmed: 28199305
doi: 10.1038/nature21060
RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11, e1001685 (2014).
doi: 10.1371/journal.pmed.1001685
White, M. T. et al. The relationship between RTS,S vaccine-induced antibodies, CD4
pubmed: 23613845
pmcid: 3628884
doi: 10.1371/journal.pone.0061395
RTS,S Clinical Trials Partnership et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284–2295 (2012).
RTS,S Clinical Trials Partnership et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863–1875 (2011).
Neafsey, D. E. et al. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N. Engl. J. Med. 373, 2025–2037 (2015).
pubmed: 26488565
pmcid: 4762279
doi: 10.1056/NEJMoa1505819
Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc. Natl. Acad. Sci. USA 114, E10438–E10445 (2017).
pubmed: 29138320
pmcid: 5715787
doi: 10.1073/pnas.1715812114
Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C. & Hill, A. V. S. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci. Rep. 7, 46621 (2017).
pubmed: 28422178
pmcid: 5395940
doi: 10.1038/srep46621
Molina-Franky, J. et al. Plasmodium falciparum pre-erythrocytic stage vaccine development. Malar. J. 19, 56 (2020).
pubmed: 32013956
pmcid: 6998842
doi: 10.1186/s12936-020-3141-z
Ferraro, B. et al. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect. Immun. 81, 3709–3720 (2013).
pubmed: 23897618
pmcid: 3811783
doi: 10.1128/IAI.00180-13
Seth, L. et al. Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. Vaccine 35, 5448–5454 (2017).
pubmed: 28274638
doi: 10.1016/j.vaccine.2017.02.040
Wang, L. T. et al. Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 17, e1010133 (2021).
pubmed: 34871332
pmcid: 8675929
doi: 10.1371/journal.ppat.1010133
Wang, L. T. et al. A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver. Immunity 53, 733–744.e8 (2020).
pubmed: 32946741
pmcid: 7572793
doi: 10.1016/j.immuni.2020.08.014
Raghunandan, R. et al. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein. Malar. J. 19, 113 (2020).
pubmed: 32183833
pmcid: 7079517
doi: 10.1186/s12936-020-03181-0
Goswami, D., Minkah, N. K. & Kappe, S. H. I. Designer parasites: Genetically engineered plasmodium as vaccines to prevent malaria infection. J. Immunol. Baltim. Md 1950 202, 20–28 (2019).
Lefebvre, M. N. et al. Expeditious recruitment of circulating memory CD8 T cells to the liver facilitates control of malaria. Cell Rep. 37, 109956 (2021).
pubmed: 34731605
pmcid: 8628427
doi: 10.1016/j.celrep.2021.109956
Hassert, M., Arumugam, S. & Harty, J. T. Memory CD8+ T cell-mediated protection against liver-stage malaria. Immunol. Rev. n/a,.
Van Braeckel-Budimir, N. & Harty, J. T. CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model. Front. Microbiol. 5, 272 (2014).
pubmed: 24936199
pmcid: 4047659
Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2, e89154 (2017).
pubmed: 28097230
pmcid: 5214067
doi: 10.1172/jci.insight.89154
Jongo, S. A. et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am. J. Trop. Med. Hyg. 99, 338–349 (2018).
pubmed: 29943719
pmcid: 6090339
doi: 10.4269/ajtmh.17-1014
Mwakingwe-Omari, A. et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature 595, 289–294 (2021).
pubmed: 34194041
doi: 10.1038/s41586-021-03684-z
Murphy, S. C. et al. A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection. Sci. Transl. Med. 14, eabn9709 (2022).
pubmed: 36001680
pmcid: 10423335
doi: 10.1126/scitranslmed.abn9709
Kublin, J. G. et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci. Transl. Med. 9, eaad9099 (2017).
pubmed: 28053159
doi: 10.1126/scitranslmed.aad9099
Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med. 22, 614–623 (2016).
pubmed: 27158907
doi: 10.1038/nm.4110
Itsara, L. S. et al. The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria. Front. Immunol. 9, 2748 (2018).
pubmed: 30619241
pmcid: 6297750
doi: 10.3389/fimmu.2018.02748
Sissoko, M. S. et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498–509 (2017).
pubmed: 28216244
pmcid: 6803168
doi: 10.1016/S1473-3099(17)30104-4
Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. 22, 377–389 (2022).
pubmed: 34801112
doi: 10.1016/S1473-3099(21)00332-7
Coulibaly, D. et al. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial. EClinicalMedicine 52, 101579 (2022).
pubmed: 35928033
pmcid: 9343417
doi: 10.1016/j.eclinm.2022.101579
Hill, A. V. S. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6, 21–32 (2006).
pubmed: 16493425
doi: 10.1038/nri1746
Fernandez-Ruiz, D. et al. Liver-resident memory CD8+ T cells form a front-line defense against malaria liver-stage infection. Immunity 51, 780 (2019).
pubmed: 31618655
doi: 10.1016/j.immuni.2019.09.019
Olsen, T. M., Stone, B. C., Chuenchob, V. & Murphy, S. C. Prime-and-trap malaria vaccination to generate protective CD8+ liver-resident memory T cells. J. Immunol. Baltim. Md 1950 201, 1984–1993 (2018).
Watson, F. et al. Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination. Am. J. Trop. Med. Hyg. tpmd211084 (2022) https://doi.org/10.4269/ajtmh.21-1084 .
Mallory, K. L. et al. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines 6, 84 (2021).
pubmed: 34145286
pmcid: 8213722
doi: 10.1038/s41541-021-00345-0
Hayashi, C. T. H. et al. mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. NPJ Vaccines 7, 155 (2022).
pubmed: 36456563
pmcid: 9715627
doi: 10.1038/s41541-022-00577-8
The ‘anti-hype’ vaccine | Nature Biotechnology. https://www.nature.com/articles/nbt.3812 (2020).
Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).
pubmed: 33053279
doi: 10.1056/NEJMoa2027906
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf.
comirnaty-epar-public-assessment-report_en.pdf.
Zhao, Y. & Huang, L. Chapter Two - Lipid Nanoparticles for Gene Delivery. in Advances in Genetics (eds. Huang, L., Liu, D. & Wagner, E.) vol. 88 13–36 (Academic Press, 2014).
Erasmus, J. H. et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci. Transl. Med. 12, eabc9396 (2020).
pubmed: 32690628
doi: 10.1126/scitranslmed.abc9396
Kimura, T. et al. A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation. Mol. Ther. 31, 2360–2375 (2023).
pubmed: 37403357
doi: 10.1016/j.ymthe.2023.06.017
Erasmus, J. H. et al. A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol. Ther. J. Am. Soc. Gene Ther. 26, 2507–2522 (2018).
doi: 10.1016/j.ymthe.2018.07.010
Zhang, M., Sun, J., Li, M. & Jin, X. Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice. Mol. Ther. - Methods Clin. Dev. 18, 702–712 (2020).
pubmed: 32913878
pmcid: 7452130
doi: 10.1016/j.omtm.2020.07.013
Leventhal, S. S. et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. EBioMedicine 82, 104188 (2022).
pubmed: 35907368
pmcid: 9335360
doi: 10.1016/j.ebiom.2022.104188
Larsen, S. E. et al. An RNA-based vaccine platform for use against mycobacterium tuberculosis. Vaccines 11, 130 (2023).
pubmed: 36679975
pmcid: 9862644
doi: 10.3390/vaccines11010130
Ljungberg, K. & Liljeström, P. Self-replicating alphavirus RNA vaccines. Expert Rev. Vaccines 14, 177–194 (2015).
pubmed: 25269775
doi: 10.1586/14760584.2015.965690
Kennedy, M. et al. A rapid and scalable density gradient purification method for Plasmodium sporozoites. Malar. J. 11, 421 (2012).
pubmed: 23244590
pmcid: 3543293
doi: 10.1186/1475-2875-11-421
Butler, N. S. et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451–462 (2011).
pubmed: 21669394
pmcid: 3117254
doi: 10.1016/j.chom.2011.05.008
Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359–1365 (2013).
pubmed: 23929949
doi: 10.1126/science.1241800
Vaughan, A. M. et al. A plasmodium parasite with complete late liver stage arrest protects against preerythrocytic and erythrocytic stage infection in mice. Infect. Immun. 86, e00088–18 (2018).
pubmed: 29440367
pmcid: 5913857
doi: 10.1128/IAI.00088-18
Goswami, D. et al. A replication-competent late liver stage-attenuated human malaria parasite. JCI Insight 5, 135589 (2020).
pubmed: 32484795
doi: 10.1172/jci.insight.135589
Putrianti, E. D., Silvie, O., Kordes, M., Borrmann, S. & Matuschewski, K. Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J. Infect. Dis. 199, 899–903 (2009).
pubmed: 19434915
doi: 10.1086/597121
Nussenzweig, R. S., Vanderberg, J., Most, H. & Orton, C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 216, 160–162 (1967).
pubmed: 6057225
doi: 10.1038/216160a0
Clyde, D. F., Most, H., McCarthy, V. C. & Vanderberg, J. P. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266, 169–177 (1973).
pubmed: 4583408
doi: 10.1097/00000441-197309000-00002
Mueller, A.-K. et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. USA 102, 3022–3027 (2005).
pubmed: 15699336
pmcid: 548321
doi: 10.1073/pnas.0408442102
Tse, S.-W., Radtke, A. J., Espinosa, D. A., Cockburn, I. A. & Zavala, F. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8
pubmed: 24823625
pmcid: 4207865
doi: 10.1093/infdis/jiu281
Tse, S.-W., Radtke, A. J. & Zavala, F. Induction and maintenance of protective CD8+ T cells against malaria liver stages: implications for vaccine development. Mem. Inst. Oswaldo Cruz 106, 172–178 (2011).
pubmed: 21881772
doi: 10.1590/S0074-02762011000900022
Tse, S.-W., Cockburn, I. A., Zhang, H., Scott, A. L. & Zavala, F. Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites. Genes Immun. 14, 302–309 (2013).
pubmed: 23594961
pmcid: 3722257
doi: 10.1038/gene.2013.20
Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).
pubmed: 34381159
pmcid: 8358000
doi: 10.1038/s42003-021-02441-2
Kumar, K. A. et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444, 937–940 (2006).
pubmed: 17151604
doi: 10.1038/nature05361
Tarun, A. S. et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J. Infect. Dis. 196, 608–616 (2007).
pubmed: 17624848
doi: 10.1086/519742
Minkah, N. K. et al. Innate immunity limits protective adaptive immune responses against pre-erythrocytic malaria parasites. Nat. Commun. 10, 3950 (2019).
pubmed: 31477704
pmcid: 6718385
doi: 10.1038/s41467-019-11819-0